Lucid Capital Markets initiates Apyx Medical stock with Buy rating

Apyx Medical (APYX) received a "Buy" initiation and $4.00 price target from Lucid Capital Markets, which highlighted the company's strategic positioning to capitalize on post-GLP-1 weight loss body contouring demand with its AYON system and perceived undervaluation at approximately 2 times enterprise value to sales. This bullish call comes despite the company's recent Q2 2025 sales miss of $11.4 million, representing a 6% year-over-year decline and falling below analyst expectations, which led Citizens JMP to maintain a "Market Perform" rating; however, Apyx is actively pursuing global expansion, including the recent launch of its Renuvion technology in China.

Analysis

Futures rise amid ongoing U.S. federal shutdown - what’s moving markets Investing.com - Lucid Capital Markets initiated coverage on Apyx Medical Corp. (NASDAQ:APYX) with a Buy rating and a $4.00 price target on Monday. The stock, currently trading at $2.39, has shown remarkable momentum with a 141% surge over the past six months, according to InvestingPro data. The research firm cited Apyx Medical’s positioning to benefit from increasing demand for skin tightening and body contouring procedures, particularly among patients who have experienced significant weight loss from GLP-1 medications. Lucid Capital Markets highlighted the company’s recent commercial launch of the AYON Body Contouring System, describing it as a comprehensive suite of services that could become essential for medical professionals offering aesthetic services. The firm noted that Apyx Medical currently trades at approximately 2 times enterprise value to sales and has limited analyst coverage, suggesting the stock may be undervalued relative to its growth potential. Apyx Medical specializes in medical devices used in aesthetic surgical procedures, with its product portfolio focused on addressing emerging trends in the post-weight loss treatment market. In other recent news, Apyx Medical Corporation reported its second-quarter 2025 financial results, showing quarterly sales of $11.4 million. This represents a 6% decline compared to the previous year and fell slightly below analysts’ expectations of $11.7 million. Analysts at Citizens JMP have maintained their Market Perform rating for Apyx Medical following these results. In a move to support its global expansion strategy, Apyx Medical has appointed two new sales executives. John Featherstone has been named Vice President of North American Sales, bringing extensive experience from previous roles in the medical device industry. Additionally, Apyx Medical has launched its Renuvion technology in China. This launch follows market clearance from the National Medical Products Administration of China and is supported by a distribution agreement with GlamMoon Medical Technology. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in APYX right now? Most investors will find it hard to answer that question with total confidence. Short of a guarantee, which no one can give you, the most successful traders stick to proven best practices without letting hype or hyper-vigilance take over their better judgment. But that doesn't mean you can't use smart shortcuts. If you're considering APYX, try chatting with WarrenAI, our powerful AI financial assistant. It's just like ChatGPT for investors, but with access to 10 years of company data, a built-in screener, Wall Street analysts' reports, and earnings call transcripts for real-time, vetted insights. Even if you end up going with your gut feeling, at least you'll know why. Apyx Medical (APYX) presents a conflicting profile for investors, juxtaposing a strong forward-looking growth narrative against recent fundamental weakness. Lucid Capital Markets has initiated coverage with a 'Buy' rating and a $4.00 price target, implying substantial upside from its current $2.39 level. The bullish thesis is predicated on the company's strategic positioning to capitalize on the growing demand for body contouring procedures following weight loss from GLP-1 medications, leveraging its new AYON Body Contouring System. Lucid also highlights a potentially attractive valuation at approximately 2 times enterprise value to sales, suggesting the stock is undervalued given its limited analyst coverage and growth prospects, a sentiment partly reflected in the stock's 141% surge over the past six months. However, this optimism is tempered by the company's Q2 2025 results, which revealed a 6% year-over-year decline in sales to $11.4 million, missing analyst estimates of $11.7 million. This performance prompted Citizens JMP to maintain a more cautious 'Market Perform' rating. To counter this, Apyx is pursuing an aggressive expansion strategy, evidenced by key appointments to its North American sales leadership and the recent launch of its Renuvion technology in China, a significant new market.

Key Decisions for Investors

• Investors with a high-risk tolerance may consider the 'Buy' rating and post-GLP-1 market thesis as a forward-looking indicator, viewing the recent sales dip as a transient issue before the growth strategy materializes.
• More cautious investors should weigh the recent 6% year-over-year revenue decline and the 'Market Perform' rating from Citizens JMP, suggesting it may be prudent to await evidence of a sales recovery before committing capital.
• Monitor the execution of the company's international expansion, specifically initial sales traction from the Renuvion launch in China, as a key catalyst that could validate the growth narrative.
• Given the stock's 141% run-up in six months, investors should assess if the potential growth from new products and markets is already partially priced in, despite the seemingly low 2x EV/Sales multiple.